5 Best Hot Stocks to Buy According to Analysts

2. vTv Therapeutics Inc. (NASDAQ:VTVT)

vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics reported its financial results for Q4 and the full-year 2025. For 2025, the company reported a net loss of $27.0 million, with R&D expenses rising to $17.9 million due to increased investment in clinical trials for cadisegliatin. The company also highlighted advancements in the development of cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes.

Throughout 2025, the company initiated patient dosing in the Phase 3 CATT1 trial and successfully expanded its scientific advisory board with internationally recognized experts. Despite a slower-than-expected start to patient recruitment, vTv Therapeutics Inc. (NASDAQ:VTVT) increased its clinical site count and engagement efforts, leading to accelerated enrollment momentum. The company now expects to complete enrollment for the CATT1 trial in Q3 2026.

There was a notable expansion of a licensing agreement with Newsoara Biopharma Inc. in February. This amendment granted Newsoara exclusive worldwide rights to vTv’s PDE4 inhibitor, HPP737, in exchange for a $20.0 million upfront payment and potential future milestones totaling up to $115 million plus royalties. Additionally, vTv Therapeutics broadened the scope of cadisegliatin by submitting a Phase 2 clinical study protocol to the Abu Dhabi Department of Health to evaluate the therapy’s efficacy and safety in patients with type 2 diabetes, marking a key step in its international research efforts.

vTv Therapeutics Inc. (NASDAQ:VTVT) is a late-stage biopharmaceutical company that develops oral small-molecule drug candidates intended to treat people living with diabetes and other chronic diseases.